Kombucha tea improves glucose tolerance and reduces hepatic steatosis in obese mice

Moreira, Gabriela V; Araujo, Layanne C. C.; Murata, Gilson Masahiro; Matos, Sandro Leão; Carvalho, Carla Roberta de Oliveira

doi:10.1016/j.biopha.2022.113660

Cited by 21 publications

(6 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(MURUGESAN et al, 2009) On the other hand, the beverage demonstrated the ability to modulate the microbiota in mice with this pathology, reducing lipid and collagen deposition in hepatocytes and regulating the expression of the hepatic FXR gene. (MOREIRA, G. V. et al, 2022) The supplementation increased the expression of CPT-1 to levels similar to the control group in the study by Mello, Materozzi, and Galli (2016). This protein is involved in mitochondrial pathways of betaoxidation and fat transport, playing a crucial role in fatty acid oxidation and triglyceride reduction.…”

Section: Hypoglycemic Propertiesmentioning

confidence: 61%

Efficiency of daily kombucha consumption in reducing glycemic levels and hypercholesterolemia

Barroso Filho,

Barros,

Ribeiro

et al. 2024

Braz. J. Hea. Rev.

View full text Add to dashboard Cite

Diabetes is one of the most common comorbidities in the world. The scientific community is constantly looking for therapeutic alternatives, pharmacological or not, to treat this disease. In this concern, an integrative review of studies published on this topic in the last ten years was carried out. Experimental studies have shown glycemic and lipid rates reduction in diabetic guinea pigs under daily kombucha consumption. Such studies showed blood sugar levels reduction of up to 56% of these specimens, as well as a significant reduction of free radicals, hepatoprotection and reduction of transaminases in these animals.

show abstract

Section: Hypoglycemic Propertiesmentioning

confidence: 61%

Efficiency of daily kombucha consumption in reducing glycemic levels and hypercholesterolemia

Barroso Filho,

Barros,

Ribeiro

et al. 2024

Braz. J. Hea. Rev.

View full text Add to dashboard Cite

show abstract

“…Interactions between bacteria and yeast species can lead to the generation of a wide variety of metabolites with functional bioactivities, such as organic acids, vitamins, and phenolic compounds, which could potentially influence the gut microbiome and overall health (Cardoso et al, 2020; Mensah et al, 2024; Mukherjee et al, 2024; Villarreal-Soto et al, 2020). Several studies in animal models have suggested that intake of microbially-rich kombucha may offer potential therapeutic benefits, such as anti-hyperglycemic, anti-oxidant and anti-inflammatory effects, and changes in the gut microbiota that are associated with improved metabolic health (Cardoso et al, 2020; Jung et al, 2019; Lee et al, 2019; Morales, 2020; Moreira et al, 2022; Wang et al, 2021; Xu et al, 2022). For instance, Jung et al demonstrated that increased relative abundance of fecal Lactobacillus and a concurrent reduction in Allobacullum, Turibacter and Clostridium relative abundances correlated with suppression of liver fat accumulation and the mitigation of nonalcoholic fatty liver disease following kombucha administration in experimental mice (Jung et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Modulating the Human Gut Microbiome and Health Markers through Kombucha Consumption: A Controlled Clinical Study

Ecklu-Mensah,

Miller,

Maseng

et al. 2024

Preprint

View full text Add to dashboard Cite

Fermented foods are surging in popularity globally due to their links to metabolic health and the gut microbiome. However, direct clinical evidence for the health claims is lacking. Here, we describe an eight-week clinical trial that explored the effects of a kombucha supplement in healthy individuals consuming a Western diet, randomized into the kombucha (n= 16) or control (n= 8) group. We collected longitudinal stool and blood samples to profile the human microbiome and inflammation markers. Paired analysis between baseline and end of intervention time points within kombucha or control groups revealed increases in fasting insulin and in HOMA-IR in the kombucha group whereas reductions in HDL cholesterol were associated with the control group. Shotgun metagenomic analysis revealed the relative abundance ofWeizmannia, a kombucha-associated probiotic to be overrepresented in consumers at the end of the intervention. Short-term kombucha intervention induced modest impacts on human gut microbiome composition and biochemical parameters.HighlightsThere is a global rise in popularity of fermented foods due to their links to metabolic health. However, empirical evidence supporting the health conferring benefits is lacking.This eight-week randomized controlled clinical trial tested the effect of kombucha on gut microbiome and inflammation in healthy participants consuming a Western diet.Biochemical indicators and inflammation markers were not different between the control and intervention groups at the end of the intervention.Kombucha-associated probiotic,Weizmanniaand short chain fatty acids synthesizing microbes were enriched in consumers after 4 weeks of kombucha intervention.Graphical abstract

show abstract

“…Srihari et al ( 21 ) reported significant decreases in glycosylated hemoglobin (HbA1c) levels in diabetic rats after 45 days of kombucha consumption, and Zubaidah et al ( 22 ) showed a significant reduction of fasting plasma glucose in diabetic rats after 28 days, also with enhanced beta cell regeneration. More recently, kombucha tea was shown to improve glycemic parameters, including glucose tolerance, and attenuate symptoms associated with nonalcoholic fatty liver disease in obese mice ( 23 ), to provide protective effects against lipopolysaccharide (LPS)-induced sepsis in LPS-challenged mice ( 24 ), and to reduce hyperglycemia in T2D-induced mice ( 25 ). In general, these effects were mediated by changes in the gut microbiota and their metabolic end-products.…”

Section: Introductionmentioning

confidence: 99%

Kombucha tea as an anti-hyperglycemic agent in humans with diabetes – a randomized controlled pilot investigation

Mendelson,

Sparkes,

Merenstein

et al. 2023

Front. Nutr.

View full text Add to dashboard Cite

IntroductionKombucha is a popular fermented tea that has attracted considerable attention due, in part, to its suggested health benefits. Previous results from animal models led us to hypothesize kombucha may reduce blood sugar levels in humans with diabetes. The objective of this pilot clinical study was to evaluate kombucha for its anti-hyperglycemic activities in adults with diabetes mellitus type II.MethodsThe study was organized as a prospective randomized double-blinded crossover study at a single-center urban hospital system. Participants (n = 12) were instructed to consume either a kombucha product or a placebo control (each 240 mL) for 4 weeks. After an 8-week washout period, participants consumed the alternate product. Fasting blood glucose levels were self-determined at baseline and at 1 and 4 weeks during each treatment period. Secondary health outcomes, including overall health, insulin requirement, gut health, skin health, mental health, and vulvovaginal health were measured by questionnaire at the same time points. The kombucha microbiota was assessed by selective culturing and 16S rRNA gene (bacteria) and ITS (fungi) sequencing. Fermentation end products were assessed by HPLC. Statistical significance of changes in fasting blood glucose was determined using paired, two-tailed student’s t-tests.ResultsKombucha lowered average fasting blood glucose levels at 4 weeks compared to baseline (164 vs. 116 mg/dL, p = 0.035), whereas the placebo did not (162 vs. 141 mg/dL, p = 0.078). The kombucha microbiota, as assessed by cultural enumeration, was mainly comprised of lactic acid bacteria, acetic acid bacteria, and yeast, with each group present at about 106 colony forming units (CFU)/mL. Likewise, 16S rRNA gene sequencing confirmed that lactic acid and acetic acid bacteria were the most abundant bacteria, and ITS sequencing showed Dekkera was the most abundant yeast. The primary fermentation end products were lactic and acetic acids, both less than 1%. Ethanol was present at 1.5%.DiscussionAlthough this pilot study was limited by a small sample size, kombucha was associated with reduced blood glucose levels in humans with diabetes. Larger follow-up studies are warranted.Clinical trial registrationClinicalTrials.gov, identifier NCT04107207.

show abstract

Kombucha tea improves glucose tolerance and reduces hepatic steatosis in obese mice

Cited by 21 publications

References 44 publications

Efficiency of daily kombucha consumption in reducing glycemic levels and hypercholesterolemia

Efficiency of daily kombucha consumption in reducing glycemic levels and hypercholesterolemia

Modulating the Human Gut Microbiome and Health Markers through Kombucha Consumption: A Controlled Clinical Study

Kombucha tea as an anti-hyperglycemic agent in humans with diabetes – a randomized controlled pilot investigation

Contact Info

Product

Resources

About